Vaxcyte, Inc. $PCVX Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC cut its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 0.6% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 2,866,305 shares of the company’s stock after selling 17,735 shares during the period. Geode Capital Management LLC’s holdings in Vaxcyte were worth $132,271,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC lifted its holdings in Vaxcyte by 33.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after buying an additional 184 shares in the last quarter. CWM LLC raised its holdings in shares of Vaxcyte by 9.0% in the 4th quarter. CWM LLC now owns 2,840 shares of the company’s stock valued at $131,000 after purchasing an additional 234 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of Vaxcyte by 0.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 31,274 shares of the company’s stock valued at $1,443,000 after purchasing an additional 252 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Vaxcyte by 3.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 14,917 shares of the company’s stock valued at $688,000 after purchasing an additional 514 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of Vaxcyte by 1.6% in the 3rd quarter. Arizona State Retirement System now owns 34,333 shares of the company’s stock valued at $1,237,000 after purchasing an additional 543 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on PCVX shares. Wall Street Zen lowered shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Jefferies Financial Group restated a “buy” rating on shares of Vaxcyte in a report on Tuesday, March 10th. BTIG Research raised their price objective on shares of Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Vaxcyte has a consensus rating of “Moderate Buy” and a consensus target price of $86.00.

Vaxcyte Stock Performance

Shares of Vaxcyte stock opened at $48.76 on Friday. Vaxcyte, Inc. has a 1 year low of $29.08 and a 1 year high of $65.00. The company has a market capitalization of $7.04 billion, a P/E ratio of -7.09 and a beta of 1.24. The company’s fifty day moving average is $55.38 and its two-hundred day moving average is $52.76.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the prior year, the firm earned ($1.04) EPS. As a group, equities analysts expect that Vaxcyte, Inc. will post -7.85 earnings per share for the current year.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 7,395 shares of the firm’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $58.88, for a total transaction of $435,417.60. Following the transaction, the chief operating officer directly owned 166,818 shares of the company’s stock, valued at approximately $9,822,243.84. This trade represents a 4.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Elvia Cowan sold 3,000 shares of Vaxcyte stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total transaction of $180,000.00. Following the completion of the sale, the chief accounting officer directly owned 28,975 shares in the company, valued at approximately $1,738,500. The trade was a 9.38% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 19,287 shares of company stock worth $1,106,319 over the last three months. 3.30% of the stock is currently owned by insiders.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.